Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle

被引:298
作者
Hayden M.R. [1 ]
Tyagi S.C. [2 ]
机构
[1] Dept. of Fam. and Community Medicine, University of Missouri, Columbia, MO
[2] Dept. of Physiology and Biophysics, University of Louisville, School of Medicine, Louisville, KY
关键词
Metabolic Syndrome; Uric Acid; Serum Uric Acid; Hyperuricemia; Serum Uric Acid Level;
D O I
10.1186/1743-7075-1-10
中图分类号
学科分类号
摘要
Background: The topical role of uric acid and its relation to cardiovascular disease, renal disease, and hypertension is rapidly evolving. Its important role both historically and currently in the clinical clustering phenomenon of the metabolic syndrome (MS), type 2 diabetes mellitus (T2DM), atheroscleropathy, and non-diabetic atherosclerosis is of great importance. Results: Uric acid is a marker of risk and it remains controversial as to its importance as a risk factor (causative role). In this review we will attempt to justify its important role as one of the many risk factors in the development of accelerated atherosclerosis and discuss its importance of being one of the multiple injurious stimuli to the endothelium, the arterial vessel wall, and capillaries. The role of uric acid, oxidative - redox stress, reactive oxygen species, and decreased endothelial nitric oxide and endothelial dysfunction cannot be over emphasized. In the atherosclerotic prooxidative environmental milieu the original antioxidant properties of uric acid paradoxically becomes prooxidant, thus contributing to the oxidation of lipoproteins within atherosclerotic plaques, regardless of their origins in the MS, T2DM, accelerated atherosclerosis (atheroscleropathy), or non-diabetic vulnerable atherosclerotic plaques. In this milieu there exists an antioxidant - prooxidant urate redox shuttle. Conclusion: Elevations of uric acid > 4 mg/dl should be considered a "red flag" in those patients at risk for cardiovascular disease and should alert the clinician to strive to utilize a global risk reduction program in a team effort to reduce the complications of the atherogenic process resulting in the morbid - mortal outcomes of cardiovascular disease. © 2004 Hayden and Tyagi; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 67 条
[1]  
Culleton B.F., Larson M.G., Kannel W.B., Levy D., Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study, Ann Intern Med, 131, 1, pp. 7-13, (1999)
[2]  
Fang J., Alderman M.H., Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey, JAMA, 283, 18, pp. 2404-2410, (2000)
[3]  
Niskanen L.K., Laaksonen D.E., Nyyssonen K., Alfthan G., Lakka H.M., Lakka T.A., Salonen J.T., Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study, Arch Intern Med, 164, 14, pp. 1546-1551, (2004)
[4]  
Freedman D.S., Williamson D.F., Gunter E.W., Byers T., Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study, Am J Epidemiol, 141, pp. 637-644, (1995)
[5]  
Alderman M.H., Uric acid and cardiovascular risk, Curr Opin Pharmacol, 2, 2, pp. 126-130, (2002)
[6]  
Verdecchia P., Schillaci G., Reboldi G.P., Santeusanio F., Porcellati C., Brunetti P., Relation between serum uric acid and risk of cardiovascular disease in essential hypertension, Hypertension, 36, pp. 1072-1078, (2000)
[7]  
Liese A.D., Hense H.W., Lowel H., Doring A., Tietze M., Keil U., Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort, Epidemiology, 10, pp. 391-397, (1999)
[8]  
Brand F.N., McGee D.L., Kannel W.B., Stokes III J., Castelli W.P., Hyperuricemia as a risk factor of coronary heart disease: The Framingham study, Am J Epidemiol, 121, pp. 11-18, (1985)
[9]  
Wannamethee S.G., Shaper A.G., Whincup P.H., Serum urate and the risk of major coronary heart disease events, Heart, 78, 2, pp. 147-153, (1997)
[10]  
Franse L.V., Pahor M., Di Bari M., Shorr R.I., Wan J.Y., Somes G.W., Applegate W.B., Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP), J Hypertens, 18, 8, pp. 1149-1154, (2000)